TG Therapeutics (TGTX) Rating Lowered to Sell at BidaskClub

TG Therapeutics (NASDAQ:TGTX) was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday.

TGTX has been the topic of several other reports. ValuEngine raised shares of TG Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Zacks Investment Research cut shares of TG Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 13th. HC Wainwright reaffirmed a “buy” rating and issued a $33.00 price target on shares of TG Therapeutics in a report on Monday, January 8th. B. Riley reaffirmed a “buy” rating and issued a $21.50 price target on shares of TG Therapeutics in a report on Monday, December 11th. Finally, Raymond James Financial reaffirmed a “buy” rating on shares of TG Therapeutics in a report on Tuesday, December 12th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $24.60.

Shares of TGTX stock opened at $14.00 on Tuesday. The firm has a market capitalization of $990.09, a PE ratio of -7.33 and a beta of 1.20. TG Therapeutics has a twelve month low of $7.25 and a twelve month high of $17.35.



TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Thursday, March 8th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, meeting the consensus estimate of ($0.46). The business had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.04 million. TG Therapeutics had a negative net margin of 77,945.40% and a negative return on equity of 145.58%. analysts anticipate that TG Therapeutics will post -1.68 EPS for the current fiscal year.

Large investors have recently modified their holdings of the business. Teacher Retirement System of Texas acquired a new stake in shares of TG Therapeutics during the fourth quarter worth $151,000. MetLife Investment Advisors LLC acquired a new stake in shares of TG Therapeutics during the fourth quarter worth $172,000. Ellington Management Group LLC acquired a new stake in shares of TG Therapeutics during the fourth quarter worth $203,000. First Mercantile Trust Co. raised its holdings in shares of TG Therapeutics by 28.6% during the fourth quarter. First Mercantile Trust Co. now owns 26,701 shares of the biopharmaceutical company’s stock worth $219,000 after purchasing an additional 5,938 shares during the period. Finally, Nexthera Capital LP acquired a new stake in shares of TG Therapeutics during the fourth quarter worth $246,000. 47.33% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “TG Therapeutics (TGTX) Rating Lowered to Sell at BidaskClub” was reported by Dakota Financial News and is the sole property of of Dakota Financial News. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://dakotafinancialnews.com/2018/04/12/tg-therapeutics-tgtx-rating-lowered-to-sell-at-bidaskclub.html.

About TG Therapeutics

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Analyst Recommendations for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply